­
­
­
­

Inventi Impact - Pharmaceutical Process Development

Patent Watch

  • Method of selling dosage forms without a prescription

    The invention features a method of selling dosage forms without a prescription. In accordance with one aspect of the invention, the dosage forms are sold in a container displayed on a retail shelf without outer secondary packaging. The container preferably is made of a material through which the dosage forms are visible. In accordance with another aspect of the invention, the container has at least one substantially flat side wall and is laid on a retail display shelf on its substantially flat side wall. The container may be formed to have only one plane of symmetry. At least one of the side walls of the container may be formed to facilitate gripping of the container.

  • Stabilised solid drug dispersions in an organic carrier and a process for preparing the same

    New solid drug dispersions are described in which a drug is present in amorphous form and dispersed within the particles of an organic carrier selected from cross-linked polymers and/or complexing agents. These dispersions are obtainable by mixing the drug and the carrier and applying an oscillating electromagnetic field in the microwave region according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes.

  • Pharmaceutical preparation comprising an active dispersed on a matrix

    The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

  • Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

    Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

  • Neoplasm specific antibodies and uses thereof

    The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.

  • Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use

    The use of L-carnitine and its alkanoyl derivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.

  • Hydrophilic/lipophilic polymeric matrix dosage formulation

    An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.

  • Process for the preparation of crystalline perindopril

    The present invention relates to a new process for the preparation of crystalline perindopril. The present invention also relates to new alkyl ammonium salts of perindopril and the processes for the preparation thereof.

  • Pharmaceutical formulations

    Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

  • Multifunctional degradable nanoparticles with control over size and functionalities

    In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymer and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  • Stable pharmaceutical products

    Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.

  • PARTICLE FORMULATIONS FOR USE IN PHARMACEUTICAL COMPOSITIONS

    A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

  • PARTICLE FORMULATIONS FOR USE IN PHARMACEUTICAL COMPOSITIONS

    A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

  • POLYSACCHARIDE COMPOSITION AND METHODS OF ISOLATION OF THE EMULSION STABILIZING CATIONIC POLYELECTROLYTIC POLYSACCHARIDE

    The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.

  • COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE

    A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

  • Pharmaceutical dosage form for immediate release of an indolinone derivative

    The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate.

  • NOVEL VEGF-2 RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF

    The invention relates to compounds of general formula (I) wherein W, D, E, G, J, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and Y are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use--alone or in combination with one or more other pharmaceutically active compounds--in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer and skin and eye diseases. ##STR00001##

  • Pharmaceutical combination

    The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

  • MEMANTINE FORMULATIONS

    The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.

  • COMPOSITION OF MATTER COMPRISING LIPOSOMES EMBEDDED IN A POLYMERIC MATRIX AND METHODS OF USING SAME

    The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes. The present disclosure also provides a method of removal of non-encapsulated active agent from the composition of matter, a method of preparing said composition of matter, a pharmaceutical composition comprising said composition of matter, use of such composition of matter; a method of providing prolonged delivery of a active agent to a subject in need thereof by administering to said subject the composition of matter disclosed herein as well as a package comprising said composition of matter held within said aqueus medium and instructions for use thereof.

  • POLYMERIC BIOLUBRICANTS FOR MEDICAL USE

    The present invention provides branched polymers which can be used as lubricants or shock absorbers in vivo. For example, the inventive polymers can be used as viscosupplements, viscoelastics, tissue space fillers, and/or anti-adhesive agents. Also provided are pharmaceutical compositions comprising the inventive polymers and methods of using them including, for example, in the treatment of arthritic and sport-injured knee joints; in reconstruction or cosmetic procedures, intervertebral disc repair, treatment of vocal cord problems, treatment of urinary incontinence, and prevention of adhesion formation following abdominal or gynecological surgery.

  • Biodegradable Microspheres and Methods of Use Thereof

    The present invention provides biodegradable microspheres, compositions comprising a subject biodegradable microsphere, and methods of using a subject biodegradable microsphere for delivery of an agent to a site in an individual.

  • PHASE TRANSITIONING HYDROGELS

    A method of forming and the resulting hydrogel composition comprising poly(vinyl alcohol) at a final concentration of about 20% (w/w) to about 65% (w/w) and polyethylene glycol at a final concentration of about 2% (w/w) to about 20% (w/w), wherein the hydrogel composition has a total polymer content, above about 30% (w/w), higher than the total polymer content of a precursor polymer solution formulated prior to the formulation of the hydrogel composition. The hydrogel composition may further comprise poly(vinyl pyrrolidone) at a fmal concentration of about 0.10% (w/w) to about 0.75% (w/w).

  • MULTICOATED ALISKIREN FORMULATIONS

    An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers.

  • METHOD OF LOADING A CRYSTALLIZATION DEVICE

    The present invention pertains to a method for loading a crystallization device and for manufacturing a crystallization device comprising multiple receptacles with a pre-defined amount of at least one matrix-forming compound capable of forming a crystallization matrix for a membrane protein, said method comprising the following steps: a) Modifying the state of aggregation of said at least one matrix-forming compound to a fluidic state which allows dispensing said at least one matrix-forming compound, and b) dispensing a defined amount of said at least one matrix-forming compound into at least one receptacle of the crystallization device, wherein said dispensed matrix-forming compound solidifies within said receptacle. Thereby, pre-filled crystallization devices are obtained which can be used as consumables in particular in automated crystallization processes. Also provided are protein crystallization methods using respectively prepared crystallization devices.

  • BIODEGRADABLE NANOPOLYMER COMPOSITIONS AND BIODEGRADABLE ARTICLES MADE THEREOF

    Biodegradable nanopolymer compositions and methods of making the compositions are provided. In a general embodiment, the present disclosure provides a biodegradable nanopolymer composition made from starting material comprising poly(lactic acid), co-polyester polymer with adipic acid compounded and nanoparticles of a mineral material such as silica and magnesium silicate. In addition, the present disclosure provides processes for making the biodegradable nanopolymer compositions as well as biodegradable articles made using the biodegradable nanopolymer compositions such as molded, formed and extruded articles.

  • SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND

    The present disclosure relates to crystallizing a chemical substance(s) using ultrasound. Methods are provided for screening a chemical substance according to its solid forms by using ultrasound to generate new or unusual solid forms. Methods are also provided for crystallizing a chemical substance by novel techniques that include sonication. The present disclosure also relates to cocrystallization using ultrasound. Methods are provided for preparing cocrystals of an active agent and a guest by sonicating and crystallizing. Methods are also provided for screening a sample according to solid state phases (such as cocrystals and salts) and include generating a cocrystal from the sample using ultrasound.

  • COMPOSITIONS AND METHODS FOR PURIFYING AND CRYSTALLIZING MOLECULES OF INTEREST

    A composition-of-matter is provided. The composition comprising at least one antibody binding moiety capable of binding an antibody-labeled target molecule, cell or virus of interest, said at least one antibody binding moiety being attached to at least one coordinating moiety selected capable of directing the composition-of-matter to form a non-covalent complex when co-incubated with a coordinator ion or molecule.

  • Spray-Dried Blood Products and Methods of Making Same

    The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.

  • PHARMACEUTICAL FORMS FOR THE RELEASE OF ACTIVE COMPOUNDS

    A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 .mu.mol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.

  • Methods for Inactivating Viruses

    The present invention provides a method for inactivating viruses, by contacting the viruses with a haloperoxidase, hydrogen peroxide, chloride ions, bromide ions, and ammonium ions.

  • METHODS AND SYSTEMS FOR BATCH PROCESSING AND EXECUTION IN A PROCESS SYSTEM

    A system and method for implementing a control process within a process control system and resolving inconsistencies during execution of the control process includes loading the logical structure of the control process, loading a plurality of instantiation objects or processes when the control process is instantiated, using the instantiation objects to instantiate a procedural element of the control process as the control process calls for the procedural element during execution, executing the procedural element as part of the control process, and deconstructing the procedural element as execution of the procedural element is completed during execution of the control process. Resolution of inconsistencies includes executing a first model of an entity in a controller, executing a second model of the entity in an execution engine, detecting a difference between the models, generating a prompt and receiving an operation instruction to continue the process or abort the process.

  • WORKFLOW PARTITIONING METHOD AND SYSTEM

    A system and method for routing and processing jobs in a production environment considers the setup characteristics of each print job. Each set of jobs may be classified as a first job processing speed set, a second job processing speed set, or another job processing speed set based on the corresponding setup characteristics. First job processing speed sets are routed to a first group of job processing resources, while second job processing speed sets are routed to a second group of job processing speed resources. Each resource group may include an autonomous cel

  • STERILIZATION SYSTEM AND DEVICE

    A system, device and method for sterilizing or decontaminating an object that by exposing the object to a sterilant gas comprised of one or more oxides of nitrogen, such as NO, NO.sub.2, NO.sub.3, N.sub.2O.sub.3, N.sub.2O.sub.4, N.sub.2O.sub.5, N.sub.2O and mixtures thereof. The source of the sterilant gas can be generated from a sterilant gas-generating composition or provided by a source of the sterilant gas.

  • USING THERMAL IMAGING FOR CONTROL OF A MANUFACTURING PROCESS

    A thermal imaging camera monitors the temperature different zones in a pharmaceutical process such as ribbon compaction, coating, spray drying, fluid bed drying, high shear wet granulation, crystallization, lyophilization, precipitation, fermentation, and low dosage dispensing of a pharmaceutically active liquid. The thermal imaging camera can be used to produce a visual display of a temperature profile, or a spray pattern. In addition, feedback from the thermal imaging camera is used to control one or more processing parameters.

  • PROCESSES OF MAKING AND USING PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS

    In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

  • TOPICAL GEL FORMULATION COMPRISING ORGANOPHOSPHATE INSECTICIDE AND PREPARATION THEREOF

    The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present gel pharmaceutical formulation preferably contains malathion and optionally contains isopropyl myristate. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same.

  • BIOLOGICALLY ACTIVE COMPOSITIONS FROM Schisandra chinensis FOR TREATING COLORECTAL CANCER

    A biologically active composition to treat colorectal cancer includes an extract of the plant Schisandra chinensis and a suitable pharmaceutical formulation. The extract can be at least one of gomisin A, angeloylgomisin H, deoxyschisandrin and gomisin N, showing activities against human tumor cell line HT-29 in the range of about 716 .mu.M to about 43 .mu.M. A suitable pharmaceutical formulation can be any one of a pill, a tablet, a capsule, a liquid solution, a liquid suspension, a powder, an intravenous solution, a gel and a suppository form. The extract is prepared by grinding the dried berries, extracting with hexane, extracting the marc with dichloromethane, extracting the dichloromethane soluble fraction with ethyl acetate, removing fatty materials in the dichloromethane-ethyl acetate soluble fraction with hexane, and fractionating the total hexane insoluble material extract using analytical high performance liquid chromatography equipped with automated repeat injection/collection cycles.

  • COMPRESSED SOLID DOSAGE FORM MANUFACTURING PROCESS WELL-SUITED FOR USE WITH DRUGS OF LOW AQUEOUS SOLUBILITY AND COMPRESSED SOLID DOSAGE FORMS MADE THEREBY

    A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing the blend into a solid, comminuting the solid into granules, wetting the granules, drying the granules, and tabletting the dried granules to make a solid pharmaceutical formulation.

  • PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM

    The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimodpharmaceutical formulation ("pump systems") and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).

  • Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol

    A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.

  • PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX

    A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

  • METHOD AND APPARATUS FOR SEALING MEDICINAL CAPSULES

    A method of sealing parts of a plastic capsule by forming a weld seam in an overlapping region of the parts of the capsule, wherein the capsule comprises a capsule cap having an open end and a capsule body having an open end, and capsules formed by such method. The capsules produced by the process according to the invention are disposable and preferably contain a single dose of a pharmaceutical formulation in the form of a powder or liquid intended to be administered by inhalation and are suitable by their form and function for use in powder inhalers or liquid nebulizers for producing aerosols. Aerosols thus produced can be inhaled, for example, in order to administer a pharmaceutical formulation to the lungs.

  • Pharmaceutical Compositions

    Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

  • DRIED PRODUCT AND A PROCESS FOR MANUFACTURING THE PRODUCT

    A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance.

  • SEALANTS, MANUFACTURING THEREOF, AND APPLICATION THEREOF

    Method comprising: applying uncured pre-gel (UP) to surface; contacting UP with cross-linking agents; allowing applied UP to cure, increasingly adhere to first surface, source of agents: solid support comprising agent, or insoluble agent salt in UP, wherein trigger compound is added to UP, or spraying/coating agent, with solid support added.

  • RECLOSABLE FLEXIBLE PACKAGING AND METHODS FOR MANUFACTURING SAME

    Flexible film packages having a partial, initial seal against ambient atmosphere and are easily openable and reclosable. The flexible film packages are generally resealable to extend the shelf-life or freshness of products contained therein once the package is initially opened. By one approach, the flexible film has two opposing edge portions that meet to form a longitudinal seal extending from a first end seal to a second end seal. The flexible film may have a score that defines a package opening. An elongated closure layer may extend over the score and may extend from a first end seal to a second end seal and within the opposing edge portions that form the longitudinal seal. The elongated closure layer may have a tack-free gripping portion used to release at least a portion of the elongated closure from the flexible film to form the package opening.

  • MULTI-PHASE MICROPARTICLES AND METHOD OF MANUFACTURING MULTI-PHASE MICROPARTICLES

    The invention relates to a method of manufacturing multi-phase microparticles. The method comprises dissolving at least three different polymers in a volatile organic solvent to obtain a first solution. The first solution comprises at least two cloud points, wherein the second cloud point is higher than the first cloud point. Viscosity of the first solution and the first and second cloud point are selected such that the at least three different polymers are immiscible with each other in the first solution. The first solution is dispersed into an aqueous continuous phase which comprises a surfactant to obtain an emulsion. The volatile organic solvent is evaporated from the emulsion. The total concentration of the at least three different polymers together in the emulsion before evaporation is below the first cloud point, or is above the first cloud point and below the second cloud point or is above the second cloud point. The invention relates also to a multi-phase microparticle made by the method and a pharmaceutical composition comprising the multi-phase microparticle.

  • Packaging Plate, Syringe-Holding Container, and Method of Manufacturing Combined Container-Syringe

    A packaging plate that supports a plurality of syringe bodies in an arranged state, including a first plate in which a plurality of support hole portions into which the syringe bodies are respectively inserted and each having a rectangular shape in plan view are formed, and an extension portion on which a flange portion of the syringe body is mounted is formed in each of these support hole portions; and a second plate that is stacked on and fixed to the upper surface of the first plate and in which through-holes through which the flange portion cannot pass are formed at locations corresponding to the support hole portions.

  • METHOD FOR MODELING A DEFECT MANAGEMENT ROUTINE IN A MANUFACTURING PROCESS AND FOR HANDLING THE DEFECT DURING THE PRODUCTION PROCESS BASED ON THE DEFECT MANAGEMENT ROUTINE

    A method models a defect management routine. Both the modeling and a handling are executed within a manufacturing execution system. During an engineering phase: modeling the production process and creating a library of possible defect types which may occur; assigning the defect types to at least one defect group; creating a library of defect specifications; creating a library of defect type specification details; creating at least one runtime defect criteria that is used to link the defect type to a certain production volume; and creating a runtime defect measurement routine that monitors a corrective measure. During a runtime production phase evaluating the product produced; identifying the respective defect type out of the library of defect types; and using the identified defect type to determine a corrective measure, a runtime defect criteria identifying the resource causing the defect type, a production volume, and to run the respective runtime defect management routine.

  • Mangiferin-Berberine Salt, Manufacturing Method and Use Thereof

    The present invention provides a mangiferin-berberine salt and manufacturing method thereof. Otherwise, the present invention also provides the use of mangiferin-berberine salt as AMPK activator.

  • CARDIOMYOCYTES-CONTAINING DEVICE AND METHOD FOR MANUFACTURING AND USING THE SAME

    Disclosed is a device for determining the cardiotoxicity of a chemical compound, comprising a substrate (10) carrying a deformable stack (34), said stack being partially detached from the substrate by a cavity (32) allowing an out-of-plane deformation of the stack, said stack comprising a first deformable layer (16), a second deformable layer (20) and a multi-electrode structure (18) sandwiched between the first and second deformable layers, the second deformable layer carrying a pattern of cardiomyocytes (28) adhered thereto; and a liquid container (26) mounted on the substrate for exposing the cardiomyocytes to the chemical compound. A method of manufacturing such a device is also disclosed. The present invention further relates to the use of the device for drug target discovery and/or drug development and a method for developing a disease model for a disease that is caused by or modified by stretching of cells, in particular a cardiac disease model.

  • INTERNET-BASED METHOD AND APPARATUS FOR CAREER AND PROFESSIONAL DEVELOPMENT VIA SIMULATED INTERVIEWS

    Methods and apparatus for generating feedback, reviewing feedback, and conducting interviews by use of VMocks are provided. A VMock, or Virtual Mock, is a virtual profile of a candidate that includes resume, text, video and a document. VMock profiles may be created that have one or more VMocks. Contacts associated with the VMock profile may be managed. Feedback may be requested from the contacts concerning the one or more VMocks, who may then generate the requested feedback. The feedback may then be reviewed. This feedback process may be performed in the context of interviews for employment opportunities and in other similar situations.

  • MATERIALS AND METHODS FOR THE DEVELOPMENT OF AN ANTIGEN-SPECIFIC IMMUNE NON-RESPONSIVENESS STATE

    The present invention provides materials and methods for making a subject non-responsive to an antigen. Methods of the invention may comprise contacting the subject with the antigen and a compound that induces anergy. In some embodiments, the antigen may be an autoimmune antigen, examples of which include, but are not limited to acetylcholine receptor for myasthenia gravis, glutamic acid decarboxylase for type I diabetes mellitus and rheumatoid factor in rheumatoid arthritis, hi some embodiments, the present invention provides a method of transplanting an organ, tissue, or cells into a subject (e.g., a mammal such as a human).

  • SCHIZOPHRENIA-RELATED ISOFORM OF KCNH2 AND DEVELOPMENT OF ANTIPSYCHOTIC DRUGS

    The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia and response to therapy.

  • Diagnostic method for the prediction of the development and control of the effectiveness of the treatment of oncological illnesses

    A diagnostic method, in which patient tissue samples are taken, microassay are prepared, specific anti-viral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: if the number of blood cells infected by any two or more viruses exceeds 50.+-.10% in patients without signs of oncological pathology, a diagnostic conclusion is drawn of a high danger of oncological illness in connection with immune system ineffectiveness; if the number of cells infected by any two or more viruses exceeds 50.+-.10% in patients with diagnosed oncological illnesses, a diagnostic conclusion of the cancer tumor's low sensitivity to chemotherapy and the perspective of quick tumor metastasis is drawn.

  • Photobioreactor for the growth and development of photosynthetic and heterotrophic microorganisms

    A photobioreactor, especially for the growth and development of photosynthetic microorganism such as microalgae or cyanobacteria. The photobioreactor includes at least one reflector (101) placed on one side of the photobioreactor and tubes arranged in a plurality of layers following one after another along a direction (N) normal to the reflector taken at a central region thereof, each layer including a plurality of tubes. Preferably, the tubes (1, 16, etc.) are straight and extend along a direction orthogonal to the normal direction (N), the reflector is cylindrical of circular or oval cross section, and the layers are cylindrical, of circular or oval cross section, and concentric.

  • GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING THE SAME

    The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved.

  • Amino Acid Compounds

    Methods for increasing the bioabsorption of amino acids and for preventing the development of nitrate tolerances in a human or animal are disclosed. The methods include administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.

  • Cancer Specific Mitotic Network

    Developed here is a mitotic network comprising a signature of up to 54 genes, and including also sub-sets of genes within the signature, which can identify members by requiring higher correlation values for a signature gene. The present mitotic network provides for methods for prognosis and diagnosis of various cancers. The mitotic network is conserved across cancers exhibiting aberrant mitotic activity and several genes in the network act as therapeutic targets. Development of other inhibitors of mitosis can apply expression values of the genes in the mitotic network from patient tissue to select patients during clinical validation of the new drugs.

  • INTEGRATED APPROACH TO THE ISOLATION AND PURIFICATION OF ANTIBODIES

    Disclosed herein is an integrated approach to purification process development and execution, including processes comprising particular capture and fine purification steps; processes that employ of a minimal number of buffer systems, and processes that make use of minimally-corrosive buffer systems, as well as combinations thereof.

  • SYSTEM AND METHOD FOR CONCEPT DEVELOPMENT

    A framework is provided for building a visual representation of a product concept including a textual component and/or a graphical component. A first element within one of the textual component and the graphical components is designated as a first dynamic element. A second element within one of the textual component and the graphical component is designated as a second dynamic element. The first dynamic element is associated with a first variant list. The second dynamic element is associated with a second variant list. A constraint is associated between at least a first element variant and at least a second element variant. A selection of a first element variant from the first variant list and a second element variant from the second variant list are received. A first instantiation of the visual representation is generated including the first element variant and the second element variant based upon the constraint.

  • SYSTEM AND METHOD FOR DETERMINING ASSET DIFFERENTIATION IN MEDICINE DEVELOPMENT

    A computer implemented system and method of determining pharmaceutical asset market potential is disclosed. The system and method comprising: collecting asset information of a proposed pharmaceutical asset; determining a therapeutic category of the proposed pharmaceutical asset; determining an unmet need for proposed pharmaceutical asset by evaluating a plurality of Customer Value Statements (CVS) based on the therapeutic category. Also disclosed, the system and method computes a differentiation score based on the plurality of CVS and comparing a strength of the proposed pharmaceutical asset against existing competitor data in the therapeutic category and computes a Real/Win/Worth (RWW) score to determine the probability of success of the proposed pharmaceutical asset in the therapeutic category based, in part, on the differentiation score; and CVS. The disclosed system and method additionally generates an executive summary report of the proposed pharmaceutical asset market potential base, in part, on the RWW score

  • METHOD OF TREATING OR RETARDING THE DEVELOPMENT OF BLINDNESS

    A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.

  • INTERNET-BASED METHOD AND APPARATUS FOR CAREER AND PROFESSIONAL DEVELOPMENT VIA SIMULATED INTERVIEWS

    Methods and apparatus for generating feedback, reviewing feedback, and conducting interviews by use of VMocks are provided. A VMock, or Virtual Mock, is a virtual profile of a candidate that includes resume, text, video and a document. VMock profiles may be created that have one or more VMocks. Contacts associated with the VMock profile may be managed. Feedback may be requested from the contacts concerning the one or more VMocks, who may then generate the requested feedback. The feedback may then be reviewed. This feedback process may be performed in the context of interviews for employment opportunities and in other similar situations.

  • Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers

    A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

  • PROCESS FOR MANUFACTURING VACCINES

    The present application discloses an improved method for conducting saccharide--protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.

  • PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS

    The present invention further relates to a process for the manufacture of compound (I), ##STR00001## wherein X is --Br or --Cl.

  • PROCESS FOR MODIFYING STARCHES

    A process for modifying starch comprises atomising an aqueous slurry of non-pregelatinised starch into an internal chamber in a bi-fluid nozzle of a spray dryer and treating the atomized slurry, in the internal chamber, with superheated steam to cause partial gelatinisation of the starch. The aqueous slurry containing partially gelatinised starch is discharged through an outlet in the internal chamber into a reactor where the droplets containing the partially gelatinised starch are subjected to further treatment with superheated steam, resulting in the completion of the gelatinisation of the starch in the reactor. Also disclosed is a bi-fluid nozzle for use in spray drying starch which comprises a nozzle body, a nozzle cap and an internal chamber located between the nozzle body and the nozzle cap. The nozzle body comprises at least one atomiser, for connection to a supply of an aqueous starch slurry, for atomising the slurry into the internal chamber and it has at least one inlet, for connection to a supply of superheated steam under pressure, for introducing superheated steam under pressure into the internal chamber. The nozzle cap comprises at least one outlet from the internal chamber. The internal chamber also comprises an interchangeable spacer element with a length of from 10 to 60 mm enabling the length of the internal chamber to be changed. A pregelatinised starch and its use in foods, especially baby foods and infant formulas, feed, pharmaceuticals, cosmetics and personal care products are also disclosed.

  • PROCESS FOR PRODUCING WINE LACTONE

    The present invention relates to a method comprising (A) reacting a .beta.-keto ester with a 2-halo ester under basic conditions to obtain a 2-aceto-3-methyl-succinic acid ester; (B) reacting the resulting 2-aceto-3-methyl-succinic acid ester with methyl vinyl ketone under basic conditions, optionally followed by a decarboxylation reaction and hydrolysis, etc., to obtain an .alpha.-methyl-.gamma.-keto acid; and (C) reducing the resulting .alpha.-methyl-.gamma.-keto acid to obtain wine lactone or a stereoisomer thereof or a mixture thereof. Alternatively, the present invention relates to a method comprising step (A) as recited above; (B) reacting the resulting 2-aceto-3-methyl-succinic acid ester with methyl vinyl ketone under basic conditions, followed by decarboxylation reaction to obtain an .alpha.-methyl-.gamma.-keto acid ester; and (E) reducing the resulting .alpha.-methyl-.gamma.-keto acid ester in the presence of a ruthenium complex having a specific structure and in the presence of a hydrogen donor to obtain wine lactone or a stereoisomer thereof or a mixture thereof.

  • DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS

    The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3' untranslated region (3'-UTR) comprising a .DELTA.30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the .DELTA.30 mutation deleted from the 3'-UTR that removes sequence in the 5' direction as far as the 5' boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3'-UTR of a dengue virus of a first serotype with the 3'-UTR of a dengue virus of a second serotype, optionally containing the .DELTA.30 mutation and nucleotides additional to the .DELTA.30 mutation deleted from the 3'-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

  • DEVELOPMENT OF C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS

    The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE. The present invention also relates to the treatment of immune thrombocytopenic purpura. Pharmaceutical compositions are also disclosed based these mutant CRP molecules.

  • METHODS AND LIPID COMPOSITIONS FOR PROMOTING DEVELOPMENT OF GUT FLORA

    Disclosed is a method of inducing and promoting development of beneficial gut flora in a subject and/or of reducing the frequency and duration of crying periods in a subject, the method comprises administering to the subject a lipid composition comprising a vegetable-derived fat source, wherein the fat source is a triglyceride fat source comprising triglycerides with 15-55% palmitic acid moieties out of the total fatty acids, and wherein the level of palmitic acid moieties at the sn-2 position of the glycerol backbone is at least 30% of total palmitic acid. The method is particularly intended for children. Specific fat sources, as well as food articles and a commercial package comprising the same are disclosed.

  • PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS

    The present invention relates to a process for the preparation of a compound of formula (I) ##STR00001## wherein R.sup.1 and R.sup.2 are as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.

  • PROCESS FOR PRODUCING ETHANOL USING A CRUDE VINYL ACETATE FEED

    Converting a crude vinyl acetate feed to ethanol by hydrogenating the acetic acid and ethyl acetate in the crude vinyl acetate feed. The crude vinyl acetate feed may comprise acetic acid and/or ethyl acetate, as well as vinyl acetate and minor amounts of vinyl propionate. The crude vinyl acetate feed may be obtained from an azeotrope column as either a sidestream or a bottom stream in a vinyl acetate production process.

  • PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES

    Converting a crude vinyl acetate feed to ethanol by hydrogenating the acetic acid and ethyl acetate in the crude vinyl acetate feed. The crude vinyl acetate feed may comprise acetic acid and/or ethyl acetate, as well as vinyl acetate and minor amounts of vinyl propionate. The crude vinyl acetate feed may be obtained from an azeotrope column as either a sidestream or a bottom stream in a vinyl acetate production process.

  • PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES

    The present invention is directed to a process for the preparation of sulfamide derivatives.

  • COPOLYMER-1, PROCESS FOR PREPARATION AND ANALYTICAL METHODS THEREOF

    The present invention relates to analytical methods such as molecular weight determination of polypeptide, in particular Glatiramer acetate. The present invention further relates to an improved process for preparation of polypeptides or pharmaceutically acceptable salts thereof, particularly Glatiramer acetate also known as Copolymer-1. The present invention further relates to characterization of Glatiramer acetate by peptide mapping.

  • PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM

    The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.

  • Process For The Preparation Of Azilsartan Medoxomil

    The present invention relates to an improved process for the preparation of azilsartan or its esters or salts thereof. Specifically, the invention provides a method for the preparation of highly pure methyl 1-[[2'-(4,5-dihydro-5-oxo-4H-1,2,4-oxa-diazol-3-yl)biphenyl-4-yl]methyl]-- 2-ethoxy-1H-benzimidazole-7-carboxylate an intermediate compound of formula (4) for azilsartan medoxomil with reduced content of desethyl impurity. The invention also involves the use of highly pure methyl 1-[[2'-(4,5-dihydro-5-oxo-4H-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-2- -ethoxy-1H-benzimidazole-7-carboxylate in the preparation of azilsartan or its esters or salts thereof, preferably medoxomil with reduced content of desethyl impurity.

  • PROCESS FOR MAKING A SOLID-STATE FORM OF AMG 706

    The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG 706 drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such an AMG 706-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous AMG 706, AMG 706 drug substance of the invention, an AMG 706-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with an anti-angiogenic is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

  • PROCESS FOR PREPARING INHIBITED NON-PREGELATINIZED GRANULAR STARCHES

    An inhibited non-pregelatinized granular starch suitable for use as a food ingredient in substitution for a chemically modified starch may be prepared by heating a non-pregelatinized granular starch in an alcoholic medium in the presence of a base and/or a salt. Steam treatment may be used to enhance the extent of inhibition.

  • PROCESS FOR THE PREPARATION OF LACOSAMIDE

    There is provided a process for the preparation of Lacosamide (which is a useful medicament) of formula I, which comprises an enantioselective enzymatic acylation. ##STR00001##

  • Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil

    The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes.

  • Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil

    The purpose of the present invention is to provide a process for producing an aqueous solution containing a fat-soluble substance. A combination of a super dissolution aid, cyclodextrin and a fat-soluble substance or a combination of the super dissolution aid and a cyclodextrin complex of the fat-soluble substance is used for dissolving the fat-soluble substance, whereby it becomes possible to provide an aqueous solution containing the fat-soluble substance at a high concentration and an aqueous solution having improved transdermal absorbability of the fat-soluble substance contained therein.

  • SOLID FORMS OF TYROSINE KINASE INHIBITORS, PROCESS FOR THE PREPARATION AND THEIR PHARMACEUTICAL COMPOSITION THEREOF

    The present invention generally relates to solid forms of tyrosine kinase inhibitors, in particular combinations of tyrosine kinase inhibitors with anti-oxidative acids, processes for its preparation and a pharmaceutical compositions containing the same.

  • NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS

    The present invention relates to a novel process for the preparation of compounds of general formula (I) ##STR00001## and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  • MICROENCAPSULATION PROCESS AND PRODUCT

    A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 .mu.m to 20 .mu.m. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract.

  • PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE

    Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included.

  • PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE

    The present invention relates to synthetic processes useful in the preparation of compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease and have application in the treatment of conditions caused by HCV. In particular, the present invention relates to novel oxidation processes useful for preparing compounds of Formula (I) and related compounds, including pharmaceutically acceptable salts, hydrates and solvates thereof, and including stereoisomers thereof. ##STR00001##

  • Process for Heat Integration for Ethanol Production and Purification Process

    Ethanol production from the hydrogenation of acetic acid requires energy to drive the hydrogenation reaction and the purification of the crude ethanol product. Heat integration process to recover heat from one part of the production process to be used within the process improves efficiencies and reduces costs.